當前位置：BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 78771NY-ESO-1 TCR (c259) CD8+ NFAT-Luciferase Reporter Jurkat Cell Line
Anti-BCMA CAR /NFAT (Luciferase) Re
Anti-CD19 CAR / NFAT (Luciferase) R
This cell line was generated from the T Cell Receptor (TCR) Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by overexpression of human CD8 (NM_001768.6) and NY-ESO-1 TCR (c259) using lentiviral transduction (CD8a Lentivirus #78648 and NY-ESO-1 -Specific TCR Lentivirus Clone c259 #78676). The human TCR clone c259 that specifically recognizes antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1).
Figure 1: Illustration of the functional co-culture assay used to validate the NY-ESO-1 TCR (c259) CD8+ NFAT-Luciferase Reporter Jurkat cell line.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供，信息內容的真實性、準確性和合法性由相關企業負責，化工儀器網對此不承擔任何保證責任。
溫馨提示：為規避購買風險，建議您在購買產品前務必確認供應商資質及產品質量。
化工儀器網